Press Releases | Norgen Biotek Corp.

Find a Press Release

Filter by title, date, or content:

Norgen Biotek Launches Another Novel First-of-Its-Kind Kit for Bacterial Extracellular Vesicles Isolation

October 29, 2025

Norgen Biotek Corp., a leading Canadian biotechnology company specializing in molecular diagnostics nucleic acid and exosome stabilization purification technologies, is proud to announce the commercial launch of its Bacterial EV Isolation Kit. The first product on the market specifically designed to isolate extracellular vesicles from bacterial samples.

Norgen Biotek Offers First-Class Products to Assist Researchers in the Study and Molecular Diagnosis of the 2019 Novel Coronavirus (COVID-19) Outbreak

March 11, 2020

THOROLD, ON, Feb. 18, 2020 /PRNewswire/ - Norgen Biotek Corp., an innovative privately held Canadian biotechnology company focusing primarily on advancing powerful tools for nucleic acid and protein stabilization and purification, today announced that they are offering a number of products to the scientific and medical community to support the study of the 2019 Novel Coronavirus (COVID-19, formerly 2019-nCoV) outbreak in humans.

Norgen Biotek's Cell-free DNA / Cell-free RNA (cf-DNA/cf-RNA) BCT Tube is Best-In-Class

February 12, 2019

THOROLD, ON, Feb. 12, 2019 /PRNewswire/ - Norgen Biotek Corp., an innovative privately held Canadian biotechnology company focusing primarily on advancing powerful tools for nucleic acid and protein stabilization and purification, today announced their unique cf-DNA/cf-RNA Preservative Tubes were found to be the most suitable for liquid biopsy when compared to other leading competitor's blood collection tubes (BCTs).

Norgen Biotek Achieves Illumina Propel Certification as a Service Provider for Next Generation Sequencing

November 20, 2018

/PRNewswire/ - Norgen Biotek Corp., an innovative privately held Canadian biotechnology company focusing primarily on nucleic acid and protein stabilization and purification, as well as providing high quality services to the scientific community, today announced that it has become Propel-Certified through Illumina as a Next Generation Sequencing (NGS) service provider. Norgen's Propel Certification covers both the NextSeq 500 System and the NextSeq 550 System.

Diversigen and Norgen Biotek Partner to Offer End-to-end Solutions for Microbiome Sample and Analysis Research

July 10, 2018

/PRNewswire/ - Diversigen Inc. (Houston, TX) and Norgen Biotek Corp. (Ontario, Canada) today announced that they have entered into a strategic partnership through which industry and academic researchers will benefit from comprehensive end-to-end logistical, sequencing, and analytical solutions to meet the growing needs for microbiome analyses.

Norgen Biotek Corp Launches New Portfolio for Next Generation Sequencing, including Library Preparation Kits and Full NGS Service Offering

July 12, 2017

/CNW/ - Norgen Biotek Corp., an innovative Canadian biotechnology company focusing primarily on advancing powerful tools for nucleic acid and protein purification and stabilization, today announced the recent launch of their new portfolio of product and service solutions for Next Generation Sequencing (NGS) applications. Norgen has extensive experience with NGS, and has leveraged this expertise to develop a number of new kits and workflows for NGS applications.

Norgen Biotek Corp. Announces Supply Agreement with Biodesix Enabling the First EML4-ALK Liquid Biopsy Test with Results in 72-Hours

March 2, 2016

/CNW/ - Norgen Biotek Corp., an innovative Canadian biotechnology company focusing on advancing powerful tools for DNA, RNA and protein stabilization and purification, today announced the signing of a supplier agreement with Biodesix, Inc. to supply novel sample preparation products based on Norgen Biotek’s proprietary purification technology. Biodesix, Inc.

Norgen Biotek Launches Novel Exosome Isolation and Exosomal microRNA Purification Kits

November 2, 2015

/PRNewswire/ - Norgen Biotek, an innovative privately held Canadian biotechnology company focusing on advancing powerful tools for nucleic acids (NA) and protein purification, today announced the launch of novel kits for the fast and simple isolation of exosomes from plasma/serum, urine, and cell culture media. These novel kits are based on the use of Norgen’s proprietary resin to purify and concentrate the exosomes. These kits are simple, rapid and scalable. Furthermore, Norgen has developed kits for the isolation of high quality RNA from exosomes.

Norgen Biotek Corp Launches over 15 Novel Kits for the Isolation of High-Quality Circulating Nucleic Acids from Blood, Plasma, Serum and Urine

September 28, 2015

/CNW/ - Norgen Biotek Corp., an innovative privately held Canadian biotechnology company focusing primarily on advancing powerful tools for nucleic acids (NA) and protein purification, today announced the launch of over 15 novel kits for the fast and simple isolation of NA from blood, plasma/serum and urine, including cell-free-circulating (cfc)RNA, cfcDNA and sequential cfcDNA and cfcRNA.

Norgen Biotek Launches a Series of DNA, RNA and Protein Ladders

February 8, 2005

Norgen Biotek Corp, an innovative Canadian biotechnology company focusing principally on advancing powerful innovations for nucleic acid and protein purification, today announced the launch and commercialization of DNA, RNA and genetically engineered Protein ladders. This is the second in a series of bio-consumable products launched by Norgen to meet the needs of scientists conducting research in genomics and proteomics.